Skip to main content

Published locations for CC-220 shows efficacy, safety concerns in phase II SLE trial

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. CC-220 shows efficacy, safety concerns in phase II SLE trial

User login

  • Reset your password
  • /content/cc-220-shows-efficacy-safety-concerns-phase-ii-sle-trial
  • /edermatologynews/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii
  • /familypracticenews/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii
  • /internalmedicinenews/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase
  • /rheumatologynews/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii
  • /rheumatology/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii-sle
  • /internalmedicine/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii
  • /dermatology/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii-sle
  • /familymedicine/article/138209/autoimmune-diseases/cc-220-shows-efficacy-safety-concerns-phase-ii-sle